Exemplary opportunity
Why GSK's Strimvelis gene therapy could be a good test for new pricing models
Glybera alipogene tiparvovec from uniQure N.V. was widely expected to be the first gene therapy to test new reimbursement models for one-shot cures, but the idea failed to gain traction. Now, Strimvelis from GlaxoSmithKline plc may provide the test case both industry and payers have been looking for.
The ex vivo gene therapy received a positive recommendation from EMA's CHMP to treat a form of severe combined immunodeficiency (SCID), but is not yet approved. GSK told BioCentury it has already had preliminary discussions with NICE, which last month released a report on new payment models for gene and cell therapy cures. The pharma also has had discussions with other undisclosed health technology assessment (HTA) authorities, payers and providers...